Monitoring Early Treatment Response of Human Primary Brain Tumors by Sodium MRI

通过钠 MRI 监测人类原发性脑肿瘤的早期治疗反应

基本信息

批准号：
8547755
负责人：
KEITH R. THULBORN
金额：
$ 14.83万
依托单位：
UNIVERSITY OF ILLINOIS AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-08-01 至 2014-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8547755
关键词：
Adult Adverse effects Anatomy Animal Experimentation Animal Model Applications Grants Area Biological Biological Markers Biopsy Blood - brain barrier anatomy Blood Volume Brain Edema Brain Neoplasms Cell Cycle Cell Density Cell Line Cell Volumes Cells Cerebral hemisphere Cerebrum Clinical Clinical Trials Combined Modality Therapy Computer software Data Diagnosis Disease Dose Early treatment Edema Environment Equilibrium Excision Experimental Models External Beam Radiation Therapy Failure Frequencies Goals Head Health Healthcare Histologic Human Image Incentives Individual Institutes Investigation Location Longitudinal Studies Magnetic Resonance Magnetic Resonance Imaging Maps Measurement Measures Methods Modeling Monitor Morbidity - disease rate Necrosis Newly Diagnosed Operative Surgical Procedures Outcome Oxygen Patient Care Patient Recruitments Patients Pattern Perfusion Phase Positioning Attribute Predictive Value Predictive Value of Tests Primary Brain Neoplasms Probability Protons Radiation Radiation Tolerance Radiation therapy Radiosurgery Recurrence Relative (related person)Resolution Sampling Site Sodium Solid Neoplasm Testing Text Time Tissues Treatment Failure United States National Institutes of Health Work active method base cell killing cell type chemotherapy conventional therapy density design effective therapy experience follow-up image registration imaging modality improved longitudinal design mortality neoplastic cell novel outcome forecast research study response success treatment response treatment strategy treatment trial trend tumor

项目摘要

DESCRIPTION (provided by applicant): The 2-year survival of patients with high-grade, primary brain tumors is only 30% with only a small further decline at 10 years to 20%. These abysmal survival figures, unchanged over the last 30 years, suggest effective local tumor control is not established during treatment. This failure is not detected by current imaging methods until months after completing treatment. Thus, vital time is lost for these patients before effective therapy can be instituted. More aggressive early local control may greatly improve treatment success if targeted therapy can be balanced against adverse side effects. Novel sodium imaging biomarkers are to be investigated for sensitivity to short- term tumor responses and for predictive value for recurrence as a first step towards customized radiation treatment of brain tumors. Regional changes in density of tumors that occur during fractionated external beam radiation treatment of primary brain tumors in humans are reflected in the changes in tissue sodium concentration, as can be measured using quantitative sodium magnetic resonance imaging. Maps of this sodium biomarker, reflecting early tumor response during fractionated radiation treatment, are to be correlated on a regional basis to the accumulated radiation dose and to tumor recurrence within a 2-year follow-up period. The goal is to determine regional sensitivity of early sodium response for predicting tumor recurrence under current standards of radiation treatment. This biomarker could be used to guide adaptive radiation therapy during initial treatment specifically to predicted areas of treatment failure. Radiobiologic models of the temporal trends in these new biomarkers will be used to estimate the radiation sensitivity parameters for tumors for the first time in individual patients. These parameters may explain regional treatment failures in terms of non- uniform radiation sensitivity in a uniform radiation treatment field. If these early changes in the sodium imaging biomarker can identify areas of ultimate treatment failure, they offer potential to tailor radiation therapy for individual patients to improve outcome. Large treatment trials can be avoided. This imaging approach is an important step on the NIH roadmap towards personalized healthcare.

描述（由申请人提供）：高级原发性脑肿瘤患者的2年生存率仅为30％，仅在10年至20％时进一步下降。在过去30年中，这些糟糕的生存数字不变，表明在治疗过程中未建立有效的局部肿瘤控制。直到完成治疗后的几个月，目前的成像方法才检测到这种故障。因此，在建立有效治疗之前，这些患者损失了重要的时间。如果靶向治疗可以与不良副作用保持平衡，则更具侵略性的早期局部控制可能会大大提高治疗的成功。应研究新型的钠成像生物标志物，以确保对短期肿瘤反应的敏感性以及复发的预测价值，这是迈向脑肿瘤定制辐射治疗的第一步。在组织钠浓度的变化中，可以使用定量钠磁共振成像来测量，在人类原发性脑肿瘤的分离肿瘤密度的区域变化反映在组织钠浓度的变化中。该钠生物标志物的图，反映了分离放射治疗期间肿瘤的早期反应，应在区域基础上与累积的辐射剂量以及在2年的随访期内与肿瘤复发相关。目的是确定早期钠反应的区域敏感性，以预测当前辐射治疗标准的肿瘤复发。该生物标志物可用于指导自适应放射疗法在初始治疗期间专门针对预测的治疗衰竭领域。这些新生物标志物中时间趋势的放射生物学模型将首次用于在个别患者中首次估算肿瘤的辐射灵敏度参数。这些参数可以解释均匀辐射治疗领域中非均匀辐射敏感性的区域治疗失败。如果钠成像生物标志物的这些早期变化可以识别出最终治疗失败的领域，则它们为各个患者提供了辐射疗法的潜力，以改善预后。可以避免大型治疗试验。这种成像方法是NIH路线图迈向个性化医疗保健的重要一步。

项目成果

期刊论文数量（9）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Ultrasmall integrin-targeted silica nanoparticles modulate signaling events and cellular processes in a concentration-dependent manner.

DOI：
10.1002/smll.201402331
发表时间：
2015-04-08
期刊：
SMALL
影响因子：
13.3
作者：
Benezra, Miriam;Phillips, Evan;Overholtzer, Michael;Zanzonico, Pat B.;Tuominen, Esa;Wiesner, Ulrich;Bradbury, Michelle S.
通讯作者：
Bradbury, Michelle S.

Motion reduction for quantitative brain sodium MR imaging with a navigated flexible twisted projection imaging sequence at 9.4 T.

通过 9.4°T 的导航灵活扭曲投影成像序列进行定量脑钠 MR 成像的运动减少。

DOI：
10.1016/j.jmr.2019.106582
发表时间：
2019
期刊：
Journal of magnetic resonance (San Diego, Calif. : 1997)
影响因子：
0
作者：
Lu,Aiming;Atkinson,IanC;Thulborn,KeithR
通讯作者：
Thulborn,KeithR

Quantitative sodium imaging with a flexible twisted projection pulse sequence.

DOI：
10.1002/mrm.22381
发表时间：
2010-06
期刊：
MAGNETIC RESONANCE IN MEDICINE
影响因子：
3.3
作者：
Lu, Aiming;Atkinson, Ian C.;Claiborne, Theodore C.;Damen, Frederick C.;Thulborn, Keith R.
通讯作者：
Thulborn, Keith R.

PCr/ATP ratio mapping of the human head by simultaneously imaging of multiple spectral peaks with interleaved excitations and flexible twisted projection imaging readout trajectories at 9.4 T.